Structure Therapeutics Inc. (GPCR) Free cash flow
- Free cash flow · 12 months (USD): Value $-224.50M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-224.50M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-220.29M − $4.21M ≈ $-224.50M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-220.29M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 1.03× | Operating cash flow / net income. Period ending 2026-06-30. $-220.29M ÷ $-214.84M ≈ 1.03× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -220.29M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 4.21M USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -224.50M USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | (m) | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -214.84M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-224.50M | (m) | $-220.29M | $4.21M | (m) | (m) | (m) | $-214.84M | (m) | (m) | (m) | 1.03× |
| 2026-03-31 | $-159.22M | (m) | $-154.74M | $4.48M | (m) | (m) | (m) | $-170.34M | (m) | (m) | (m) | 0.91× |
| 2025-12-31 | $-225.81M | (m) | $-222.20M | $3.61M | (m) | (m) | (m) | $-141.20M | (m) | (m) | (m) | 1.57× |
| 2025-09-30 | $-196.38M | (m) | $-194.25M | $2.13M | (m) | (m) | (m) | $-210.69M | (m) | (m) | (m) | 0.92× |
| 2025-06-30 | $-164.20M | (m) | $-162.95M | $1.25M | (m) | (m) | (m) | $-178.95M | (m) | (m) | (m) | 0.91× |
| 2025-03-31 | $-136.23M | (m) | $-134.78M | $1.44M | (m) | (m) | (m) | $-143.32M | (m) | (m) | (m) | 0.94× |
| 2024-12-31 | $-117.93M | (m) | $-116.64M | $1.29M | (m) | (m) | (m) | $-122.53M | (m) | (m) | (m) | 0.95× |
| 2024-09-30 | $-104.33M | (m) | $-101.90M | $2.43M | (m) | (m) | (m) | $-110.55M | (m) | (m) | (m) | 0.92× |
| 2024-06-30 | $-105.32M | (m) | $-102.76M | $2.56M | (m) | (m) | (m) | $-100.44M | (m) | (m) | (m) | 1.02× |
| 2024-03-31 | (m) | (m) | $-93.26M | (m) | (m) | (m) | (m) | $-97.68M | (m) | (m) | (m) | 0.95× |
| 2023-12-31 | $-81.66M | (m) | $-79.49M | $2.17M | (m) | (m) | (m) | $-89.62M | (m) | (m) | (m) | 0.89× |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $-46.27M | (m) | $-46.12M | $155.00K | (m) | (m) | (m) | $-51.32M | (m) | (m) | (m) | 0.90× |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |